Avantor, Inc. (NYSE:AVTR) Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund raised its position in Avantor, Inc. (NYSE:AVTR) by 0.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 138,465 shares of the company’s stock after purchasing an additional 765 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Avantor were worth $2,917,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Public Employees Retirement System of Ohio increased its holdings in Avantor by 34.1% in the third quarter. Public Employees Retirement System of Ohio now owns 346,822 shares of the company’s stock valued at $8,972,000 after buying an additional 88,205 shares during the last quarter. Perpetual Ltd boosted its position in shares of Avantor by 38.7% during the 4th quarter. Perpetual Ltd now owns 1,766,882 shares of the company’s stock worth $37,228,000 after acquiring an additional 493,408 shares in the last quarter. New York State Teachers Retirement System purchased a new position in shares of Avantor in the 3rd quarter valued at about $8,473,000. Everence Capital Management Inc. acquired a new stake in shares of Avantor during the 4th quarter worth about $555,000. Finally, Rhumbline Advisers lifted its stake in Avantor by 1.8% during the fourth quarter. Rhumbline Advisers now owns 1,922,368 shares of the company’s stock worth $40,504,000 after purchasing an additional 33,692 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Stifel Nicolaus dropped their price target on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. Barclays cut their price target on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Morgan Stanley reduced their price target on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Royal Bank of Canada dropped their price objective on Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a report on Monday, February 10th. Finally, Raymond James reissued an “outperform” rating and issued a $24.00 target price (down from $26.00) on shares of Avantor in a report on Monday, February 10th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $25.92.

Avantor Stock Performance

Shares of AVTR stock opened at $16.50 on Friday. The stock’s 50-day moving average price is $20.60 and its 200 day moving average price is $22.74. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $11.23 billion, a PE ratio of 15.86, a price-to-earnings-growth ratio of 1.55 and a beta of 1.28. Avantor, Inc. has a 52-week low of $16.46 and a 52-week high of $28.00.

Avantor (NYSE:AVTR) last released its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same period last year, the company earned $0.22 EPS. As a group, equities research analysts forecast that Avantor, Inc. will post 1.06 EPS for the current year.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.